Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
THE outgoing chief of retail giant John Lewis has taken aim at last month's Budget, describing its impact on businesses as a "two-handed grab" that will burden retailers with millions in extra costs.
Nish Kankiwala, who is wrapping up his two-year stint as the head of John Lewis and Waitrose, expressed particular concern about the changes to employer National Insurance contributions and the lack of meaningful business rates reform.
"If they could delay the national insurance [changes], but also if they could fundamentally bring forward a radical reshaping of business rates, I think it will make a massive difference," Kankiwala told The Financial Times. "Not just for small and medium enterprises, but I think for retail generally. It's very important."
The budget, unveiled by chancellor Rachel Reeves, will increase employer National Insurance to 15 per cent from April - a 1.2 percentage point rise. The move aims to help plug a £40 billion funding gap but has sparked worry among retailers.
Shop owners are especially frustrated by the government's failure to address the gap between business rates paid by high street shops and online retailers like Amazon. The British Retail Consortium estimates these changes will cost businesses £7bn annually and warns this could lead to job losses and price hikes for shoppers.
Despite facing "tens of millions" in additional costs next year, Kankiwala promised that John Lewis would try to protect customers from price increases. "The last thing we need is a resurgence of inflation, because we just got that under control, and inflation is not good for anybody," he was quoted as saying. "We will try and control [pricing] as much as possible."
The Treasury has defended its decisions, saying it "had to make difficult choices to fix the foundations of the country and restore desperately needed economic stability to allow businesses to thrive."
John Lewis recently returned to profit after three years of losses caused by high street competition, rising inflation, and pandemic-related shop closures.
Kankiwala, who became the partnership's first chief executive last March, insists these new costs won't derail the company's growth plans.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.